<DOC>
	<DOC>NCT00700830</DOC>
	<brief_summary>This study is conducted in Africa. The aim of this study is to assess the safety and efficacy of Levemir® treatment for insulin naive patients with type 2 diabetes under normal clinical practice conditions in Algeria.</brief_summary>
	<brief_title>Observational Study to Evaluate the Safety and Efficacy of Levemir® in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Informed consent obtained before any trialrelated activities Type 2 diabetes HbA1c between 79% Insulin naive Inadequate control with oral antidiabetics therapy as judged by investigator Patients with type 1 diabetes Hypersensitivity to Levemir® or to any of the excipients Pregnancy, or desire of pregnancy within next 6 months HbA1c greater than or equal to 9% Known or suspected allergy to the trial product or to any of the excipients Subjects who are unlikely to comply with protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>